
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts

Advancing Regulatory Validation Taletrectinib for Enhanced NSCLC Treatment
The MHRA’s validation of Nuvation Bio’s marketing authorisation application marks an important regulatory validation taletrectinib for adults with advanced ROS1-positive non-small cell lung cancer. This milestone, achieved via the International Recognition Procedure in parallel with EMA review, f...

Global Impact of Portuguese Biotech Innovation
Portuguese Biotech Innovation has matured into a compelling global force, with Solfarcos marking a decade of translating University of Minho research into commercial technologies that span cosmetics and pharmaceuticals. The Braga-based spin-off has built a unified platform of peptides and protein...

Exposing Cannabis Regulatory Exploitation in Portugal’s Medicinal Sector
Portugal’s medicines regulator INFARMED has been shaken by a major case of cannabis regulatory exploitation in which criminal networks weaponised medicinal cannabis licences to traffic drugs on an industrial scale. Insufficient inspectors, rapid sector growth and the recruitment of former agency ...